ClinicalTrials.gg
Not yet recruitingNCT06404229Updated May 8, 2024

Use of CPETarm for Risk Stratification of Patients With CLTI

An interventional study of CardioPulmonary Exercise Testing in Chronic Limb-Threatening Ischemia and Surgery-Complications, sponsored by University of Manchester. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University of Manchester · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · United Kingdom.

Planned enrollment
3rd of 12
120 · median 49
Started
2024
with 2 others
No phase
7 of 23
1 open now
Registered
18th of 23
by date

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 with no phase, and was the 18th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a prospective cohort study of patients undergoing surgery for chronic limb threatening ischaemia. Prior to surgery, patients will undergo CardioPulmonary Exercise testing (CPET) using an arm ergometer. Feasibility outcome measures will be recorded at testing and participants will be followed up for a period of up to 5 years to obtain clinical outcome measures.

Read the detailed description

Chronic limb-threatening ischaemia (CLTI) is the most severe clinical manifestation of peripheral arterial disease, defined by the presence of pain at rest and/or tissue loss affecting the legs. It is a major cause of chronic pain, amputation and death. CLTI is a growing global healthcare problem attributable to the ageing population and increase of risk factors such such as diabetes.

Prevalence of high blood pressure, heart disease and diabetes is high amongst this cohort of patients and so it is unsurprising that surgery is associated with an alarmingly high risk of illness, complications and even death when compared to other types of surgery. As nearly half of the patients present as an emergency, assessment and optimisation of health prior to surgery is challenging.

The aims of the assessment prior to surgery includes optimising any current health problems, understanding what care may be required after surgery, allowing the patient to be fully informed of the risks and considering non surgical options where appropriate. Inadequate risk stratification can lead to delays in theatre, increased length of hospital stay and unnecessary loss of limb and/or life.

Currently there is no established method to risk stratify CLTI patients presenting as an emergency. CardioPulmonary Exercise Testing (CPET) is an exercise test useful in identification of a number of heart and lung conditions. The test is established for risk-stratification in other populations but its method of using a bicycle is not suitable for CLTI patients, nor has it previously been used in the emergency setting. This study will assess whether CPET using arm exercise instead of the traditional bicycle is a feasible test that can be performed at the bedside within 48 hours of intention to treat, required to make it a practical test in the assessment of emergency patients.

Hypothesis:

  1. Cardiopulmonary exercise testing using an arm ergometer (CPETarm) is a feasible, acceptable and safe tool to use at the 'bedside' in patients undergoing emergency surgery for chronic limb threatening ischaemia (CLTI).
  2. Values obtained from CPETarm and/or hand grip strength can be used to predict post operative outcomes including major adverse cardiovascular events and mortality for this group of patients.

Recruitment:

The study will enrol 120 consecutive, eligible and consenting patients admitted with with CLTI to the Manchester Vascular Centre at Manchester University National Health Service Foundation Trust. Patients scheduled to undergo non elective surgical or endovascular treatment of their chronic limb threatening ischaemia will be screened for inclusion. Decision for surgery/management will be recommended by their Consultant Vascular Surgeon.

03

Conditions studied

  • Chronic Limb-Threatening Ischemia
  • Surgery-Complications

Keywords

  • CardioPulmonary Exercise Testing
  • Risk Stratification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and willingness to give written
  • Diagnosis of chronic limb threatening ischaemia, undergoing one of the following procedures: Infra inguinal bypass, Extra anatomical bypass, Common femoral endarterectomy, Endovascular treatment, Primary amputation

Exclusion criteria

Exclusion Criteria:

  • Patients with active medical conditions deemed an absolute for undertaking CPET
  • Ongoing evaluation for coronary artery disease (e.g awaiting stress test or cardiac catheterisation or requiring the up titration of anti anginal medications)
  • Active arrthymic requiring the initiation or up titration of an anti arrthymic medication
  • Active congestive cardiac failure requiring the initiation or up titration of diuretic therapy.
  • Severe cardiac valvular stenosis
  • Physical disability precluding ability to perform CPETarm
  • Psychiatric disorder or dementia precluding them from consenting for research and/or undertaking testing and/or follow up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    CardioPulmonary Exercise Testing

    All patients included in the study will perform CardioPulmonary Exercise Testing prior to surgery

    Diagnostic Test: CardioPulmonary Exercise Testing

Interventions

  • Diagnostic testCardioPulmonary Exercise Testing

    CardioPulmonary Exercise Testing using an arm ergometer prior to surgery

06

What researchers measure

Primary outcomes

  1. Acceptability of bedside CPET

    The percentage of recruited participants actually performing CPET compared to the number of patients consenting. (A) identifying reasons, and their number, as to why participants did not undertake CPET, and (B) identifying reasons, and their number, for clinician-led termination of CPET

    Time frame: At time of CPET testing (1 day)

  2. Recruitment rate (uptake of bedside CPET)

    The percentage of eligible patients who gave informed consent to participate in the study

    Time frame: At time of CPET testing (1 day)

  3. Practicality of bedside CPET

    Recorded as three variables 1. Time between decision for surgical intervention and CPET testing 2. Location of testing 3. Duration of testing (inclusive of set up, patient instructions, completion of test and recovery)

    Time frame: At time of CPET testing (1 day)

  4. Patient reported outcome measures

    Established by identifying participant opinions on satisfaction with, and suitability of, CPET for future use. Assessed in a qualitative manner using a semi structured interview with 8 pre determined questions and quantitatively using a 5 point Likert scale for 12 statements, whereby 1='strongly disagree' and 5='strongly agree'.

    Time frame: 30 days

  5. Adverse or unexpected events report

    Defined as participants experiencing serious adverse events during or after the test. Defined adverse events for CPET as: 1) death during the stress test, 2) external defibrillation or implantable cardioverter-defibrillator discharge, 3) sustained ventricular tachycardia (wide complex tachycardia lasting longer than 30 seconds), 4) myocardial infarction, 5) syncope, 6) administration of advanced cardiac life support medications, 7) referral for direct hospital admission, or 8) referral to emergency department

    Time frame: At time of CPET testing (1 day)

Secondary outcomes

  1. Peri-operative complications

    Defined as defined as any complication that occurred during surgery or within 30 days of surgery. Graded using the Clavien-Dindo classification.

    Time frame: Recorded at 30 days

  2. All cause mortality

    Defined as death from any cause during the study

    Time frame: Recorded at 30 days, 90 days, 1 year, 3 years and 5 years

  3. Amputation-free survival

    Freedom of death and major limb amputation during the study

    Time frame: Recorded at 30 days, 90 days, 1 year, 3 years and 5 years

  4. Level of care post-surgery

    Categorised as according to the ward the patient is cared for in the immediate post operative period. * Level 0 (postoperative recovery on a surgical ward * Level 1 (postoperative recovery on a surgical ward with access to a critical care outreach team) * Level 2 (high dependency unit, post anaesthesia care unit) * Level 3 (intensive care unit)

    Time frame: Recorded at 30 days

  5. Higher level of care length of stay

    Recorded as the length of stay on a ward categorised as level 2 or 3.

    Time frame: Recorded at 30 days

  6. Length of hospital stay

    Defined as number of days spent in index hospital from date of operation.

    Time frame: Recorded at 30 days

  7. Discharge destination

    Recorded as place of discharge from hospital. Discharge destination, dichotomized as home or non-home. Non-home discharge was defined as discharge to a skilled care facility (e.g., a transitional care unit, subacute hospital, or skilled nursing home), unskilled care (e.g., nursing home or assisted facility, only if this was not the patient's preoperative location), separate acute care, rehabilitation, or a multi-level senior community)

    Time frame: Recorded at 30 days

  8. Rate of re-intervention

    Primary patency: Freedom from occlusion of bypass-graft or endovascular treated arterial segment and freedom of restenosis that need intervention in bypass-graft or endovascular treated arterial segment. Secondary patency: Freedom from occlusion of bypass-graft or endovascular treated arterial segment. Treated for restenosis in bypass-graft or endovascular treated arterial segment.

    Time frame: Recorded at 30 day and 90 days

  9. Hospital readmission rate

    Defined as a readmission after discharge from the index hospital stay and within 90 days of the primary surgical procedure

    Time frame: Recorded at 30 and 90 days.

  10. Health related quality of life

    Health related quality of life measured by The Vascular Quality of Life Questionnaire 25 (VASCUQOL25). VascuQol consists of 25 items, subdivided into five domains. Each question has a seven-point response scale. The responses are averaged to give an overall and a domain score ranging from one (worst Health Related Quality of Life, HRQoL) to seven (best HRQoL).

    Time frame: Recorded at 30 and 90 days

  11. Major adverse cardiovascular events

    Defined as non fatal myocardial infarction, non fatal stroke, cardiovascular death, coronary intervention or unstable angina requiring hospitalisation.

    Time frame: Recorded at 30 and 90 days

07

Study locations

1 site
  • University of Manchester
    Manchester, Greater Manchester M13 9PL, United Kingdom
    • Mr Jonathan Ghosh · ContactJonathan.Ghosh@manchester.ac.uk
    • Adam Haque, MBChB, PGCert, MSc, PhD, MRCS · Sub investigator
    • Stacie Hodge, MBChB, BsC, MRCS · Sub investigator
    • Jonathan Ghosh, MBChB MRCS MD MA FRCS · Principal investigator
08

References and documents

Publications

  • [1] Conte MS, Bradbury AW, Kolh P, et al. GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. Eur J Vasc Endovasc Surg, 2019. 58: p. 1-109.
  • [2] Waton S, Johal A, Li Q, et al. National Vascular Registry: 2023 State of the Nation Report. London: The Royal College of Surgeons of England, November 2023.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for May 2025, 12 months later.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
May 8, 2024
StartEst.
May 28, 2024
Primary completionEst.
May 28, 2025
CompletionEst.
Apr 28, 2030
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06404229
Responsible party
Jonathan Ghosh (Honorary Reader Cardiovascular Sciences, Consultant and Clinical Director, University of Manchester) — Principal investigator
First posted
May 8, 2024
Start date
May 28, 2024 (estimated)
Primary completion
May 28, 2025 (estimated)
Completion
Apr 28, 2030 (estimated)
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion